BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is extremely pleased to announce that it has entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.
“We are extremely pleased with this agreement with Hadassah”
Hadassah’s Helsinki Committee has approved the commencement of clinical trials with BrainStorm on condition of approval by the National Helsinki Committee of Israel’s Ministry of Health.
Hadassah is an internationally recognized medical facility and has vast medical expertise in treating patients through the use of stem cell therapies. BrainStorm’s differentiated stem cells have proven more effective on animal models as compared to other stem cell therapies.
The agreement that was signed with Hadassah, through its technology transfer company Hadasit Medical Research Services and Development Co. Ltd., calls for the Company’s ALS clinical trials to be performed at Hadassah utilizing Hadassah’s state-of-the-art medical facility and physicians and their experience with injecting patients with mesenchymal stem cells.
The agreement also provides the Company with the use of a dedicated laboratory and equipment. Work at the lab will be carried out by the Company's employees under the supervision of the Company’s supervisor together with Hadassah’s supervisor of good manufacturing practice standards.
Professor Dimitrios Karussis, of Hadassah's Department of Neurology, and the Principal Investigator from Hadassah, stated: “Professor Ben Hur, the Head of the department of Neurology, and I, strongly believe in BrainStorm and its technology. We are delighted to join our efforts at Hadassah with BrainStorm and perform the first clinical trials in ALS, with these types of modified stem cells. Based on our previous clinical experience with mesenchymal stem cells and the impressive preclinical data from BrainStorm, and after receiving final approval of the Ministry of Health, we believe that together we may achieve a breakthrough for the treatment of people suffering from ALS.”
“We are extremely pleased with this agreement with Hadassah,” stated Rami Efrati, CEO of BrainStorm. “Hadassah is a world renowned medical organization with proficiency in stem cell therapy and has been providing stem cell treatments to patients for quite some time. This agreement provides BrainStorm with the medical expertise and support needed to conduct its first ALS clinical trials at a leading medical center in Israel and the Middle East. Along with the funds we secured last week, we now have in place all that we need to proceed with our ALS clinical trials and only await approval from the Israeli Ministry of Health which we hope we will receive in the coming weeks.”
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics